ABX464 for ulcerative colitis and other inflammatory diseases
Abivax developed ABX464 from the company’s chemical library of >1200 small molecules that have the potential to modulate RNA splicing. The resulting effects of ABX464's RNA splicing constitute a potent anti-inflammatory action, as well as an ability to reduce viral reservoirs of HIV.
Abivax is utilizing ABX464’s anti-inflammatory properties to target inflammation in clinical trials. The discovery of ABX464’s anti-inflammatory properties prompted the initiation of studies which position ABX464 as a drug candidate with the potential to treat ulcerative colitis and other inflammatory diseases.
How does ABX464 address inflammation?
ABX464’s anti-inflammatory effect is triggered by the molecule binding to its target, the cap binding complex (CBC), located on the 5' end of every cellular non-coding RNA molecule. This binding results in the splicing of a long, non-coding RNA, that induces the overexpression of a single micro-RNA product, miR-124. miR-124 initiates a cascade which is believed to propagate the anti-inflammatory effect that has been observed in preclinical models.
IBD – a chronic disease with no cure
Inflammatory bowel disease broadly describes conditions characterized by chronic inflammation of the digestive tract. The two major types of IBD are ulcerative colitis (UC) and Crohn’s disease (CD). While CD can affect any part of the gastrointestinal tract, UC only affects the colon and causes inflammation that can lead to rectal bleeding, bloody diarrhea, abdominal cramps, and severe pain. ABX464 is being studied in UC, the exact cause of which remains unknown. However, a dysregulated immune system and genetic influence are possible causes. UC can be debilitating and can lead to life-threatening complications. Although treatment for UC has improved significantly in recent years, there is still no cure, and patients often become resistant to current treatments, demonstrating a substantial unmet need. To learn more about UC and IBD, go to: